Initial Phase 1 Clinical Data Expected Next Year

ABL Bio, a company specializing in bispecific antibodies, announced on May 28 that NEOK Bio has completed dosing the first patient in the U.S. Phase 1 clinical trial of its bispecific antibody-drug conjugate (ADC) candidates ABL206 (NEOK001) and ABL209 (NEOK002). NEOK Bio is a U.S.-based biotechnology company established by ABL Bio and is responsible for the global development and commercialization of ABL206 and ABL209.

ABL Bio and NEOK Bio Complete First Patient Dosing in U.S. Phase 1 Trial of ABL206 and ABL209 View original image

Bispecific antibody ADCs are next-generation anticancer technologies that simultaneously target two complementary antigens expressed on cancer cells, precisely delivering a potent payload to the cancer cells. This approach enhances therapeutic efficacy while reducing damage to normal cells.


ABL206 is a first-in-class bispecific antibody ADC that targets both B7-H3 and ROR1, utilizing a payload from the topoisomerase I inhibitor class. In preclinical studies, ABL206 demonstrated improved efficacy and safety compared to single-antibody ADCs targeting either ROR1 or B7-H3. Additionally, GLP toxicity tests in non-human primates confirmed an overall favorable tolerability profile.


ABL209 is a bispecific antibody ADC candidate that simultaneously targets EGFR and MUC1, and like ABL206, employs a topoisomerase I inhibitor class payload. By targeting both EGFR and MUC1, ABL209 is expected to reduce the skin toxicity commonly observed with EGFR-targeted therapies, while also overcoming the limited efficacy caused by varying expression levels of MUC1 across cancer types and the phenomenon of antigen shedding.


NEOK Bio plans to evaluate the safety, tolerability, and efficacy of ABL206 and ABL209 through this Phase 1 clinical trial, and anticipates obtaining initial clinical data in 2027.


Lee Sanghoon, CEO of ABL Bio, stated, "While the single-antibody ADC market, sparked by Enhertu, has already become a fiercely competitive red ocean, bispecific antibody ADCs represent a blue ocean that is just beginning to emerge. As many clinical-stage bispecific ADC candidates are being developed by Chinese biotech companies, NEOK Bio is drawing attention for its distinction as a U.S. company and its rapid development pace, placing it among the leading group. With NEOK Bio's ADC development experts leading the clinical development of ABL206 and ABL209, we expect meaningful results from the upcoming Phase 1 trials."



Mayank Gandhi, CEO of NEOK Bio, commented, "Advancing both candidates from preclinical development to first patient dosing in Phase 1 in such a short time demonstrates the operational efficiency and execution capabilities of our bispecific ADC development team. The bispecific ADC approach holds the potential to provide more effective treatment options for patients with hard-to-treat solid tumors."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing